Full-Time
Senior Clinical Research Associate/Clinical Trial Manager
Updated on 9/3/2026
BridgeBio
1,001-5,000 employees
Develops therapies for genetic diseases
Compensation Overview
$135k - $177k/yr
San Francisco, CA, USA
Remote
Remote within the United States, with quarterly or as-needed visits to the San Francisco office.
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to BridgeBio
See people who can refer or advise you
- Bachelor's degree or equivalent training and experience, such as registered nurse/physician assistant or Bachelor of Science in Nursing training.
- A minimum of 4-6 years of clinical study experience.
- Experience supporting global studies in a fast-paced environment.
- Successful experience working with contract research organizations and vendors.
- Excellent communication skills and the ability to achieve milestones in a team environment.
- Ability to communicate and collaborate respectfully in a remote environment.
- Collaborate within the Clinical Operations team to support the timely conduct of clinical studies according to protocols, Good Clinical Practice, standard operating procedures, and applicable regulations.
- Perform quality study oversight processes, including monitoring communications with site staff and clinical vendors and reviewing monitoring trip reports.
- Partner with the Clinical Operations Study Lead and cross-functional team to support clinical studies from planning and start-up through execution, maintenance, and close-out in accordance with assigned standard operating procedures, ICH Good Clinical Practice, and corporate and departmental goals.
- Lead operational management for assigned regions and sites by monitoring performance metrics, identifying and mitigating risks, driving escalations and action-item closure, and representing regional performance in study-team and cross-functional discussions.
- Serve as the primary sponsor contact for assigned investigators and study sites, building relationships and supporting communication and issue resolution.
- Lead aspects of vendor management for contract research organization and other key vendors, including interactive response technology, imaging, central laboratories, and specialty laboratories; establish expectations, ensure deliverables are met, maintain performance measures, escalate issues, address performance gaps, and drive corrective actions to closure.
- Provide oversight of contract research organization monitors by reviewing monitoring documentation, evaluating monitor and site performance, conducting oversight or co-monitoring visits as needed, and identifying cross-site or systemic risks.
- Maintain and analyze study tracking tools and operational metrics covering site start-up, screening, enrollment, study visits, data entry, query resolution, and monitoring activities.
- Contribute to the development and maintenance of study documents, including informed consent forms, site training materials, case report forms, monitoring plans, source document templates, protocols, investigator brochures, and regulatory submission materials under the direction of the study lead.
- Ensure the Trial Master File is complete, current, accurate, and inspection-ready, and drive resolution of missing or deficient documentation.
- Assist with shipment and reconciliation of investigational product at study and site level as needed.
- Apply ICH E6(R3) Good Clinical Practice principles, including quality by design, risk-proportionate oversight, critical-to-quality factors, participant protection, and reliable trial results, across study activities.
- Escalate concerns regarding timelines, milestones, resourcing, and potential study-execution issues to the Study Lead.
- Exercise sound judgment to resolve or seek expert input on protocol and drug questions, safety, regulatory, and legal questions.
- Oversee operational study needs, including clinical supplies.
- Participate in the review and negotiation of site budgets and contracts.
- Support and participate in Investigator Meetings and other study-related meetings as required.
- Promote a collaborative, respectful, quality-focused work environment.
- Perform additional Clinical Operations activities as assigned.
- Travel as required to carry out responsibilities, up to 20%.
- Experience working within a biotechnology or pharmaceutical sponsor organization.
- Prior experience as a monitoring Clinical Research Associate, including site initiation, interim monitoring, and close-out visits.
- Experience maintaining or overseeing Trial Master Files, including document completeness, quality, timeliness, and inspection readiness.
- Working knowledge of ICH E6(R3) Good Clinical Practice principles and risk-based quality management.
- Experience using Microsoft Office Suite, including Excel, Word, and PowerPoint, and SmartSheet.
BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2014
Get referred to BridgeBio
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $243.7 million; Attruby sales hit $222.4 million.
- Attruby first-half 2026 sales reached $403 million, with treatment-naive share still rising.
- ENCAleret and infigratinib are under FDA review, creating multiple launch catalysts through 2027.
What critics are saying
- Attruby concentration is extreme; any reimbursement or safety slip before 2027 crushes growth.
- BBP-418 faces a November 27, 2026 FDA decision; a CRL would damage credibility.
- Tafamidis remains the entrenched ATTR-CM rival; payers can force step-edits and slow switching.
What makes BridgeBio unique
- Acoramidis/Attruby is approved globally and showed 54-month survival benefit at ESC 2026.
- BridgeBio’s decentralized model pushes three NDAs simultaneously: BBP-418, encaleret, infigratinib.
- BBP-418 could become the first approved therapy for LGMD2I/R9, per May 2026 FDA filing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Performance Bonus
Company Equity
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -3%2 year growth
↑ 1%Lionsbridge Wealth Management LLC acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,453 shares of the company’s stock, valued at approximately $704,000. A number of […]
BridgeBio to present new data on the impact of Oral Infigratinib on medical complications in achondroplasia at the Annual ESPE Meeting 2026. PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026. In addition to the late-breaking oral presentation, two posters and one eposter will be shared on longer-term data for oral infigratinib in achondroplasia, PROPEL I&T-an ongoing Phase 2/2b study in children under 3 years old with achondroplasia, and qualitative research on the impacts of hypochondroplasia. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions, which hold significant unmet needs for families. Late-Breaking Oral Presentation: A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia: Results from the PROPEL 3 Study Presenter: Julie Hoover-Fong, M.D., Ph.D., Johns Hopkins University, U.S. Date: Wednesday, September 9 at 10:00 am CEST Posters: Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK PROPEL Infant and Toddler: Study Design and Ongoing Enrollment of a Phase 2/2b Study of Infigratinib in Children under 3 Years Old with Achondroplasia Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK ePoster: Potential Medical Challenges and Functional Impacts of Hypochondroplasia: Qualitative Interviews with Children and Parents Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK About Achondroplasia Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating variant in FGFR3. About Oral Infigratinib Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3. About BridgeBio BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. Africa Daily Journal aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Its decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow Africa Daily Journal on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. BridgeBio Media Contact: Kaitlyn Reilly, Director, Communications [email protected] (650) 789-8220 BridgeBio Investor Contact: Kristen Kelleher, Director, Investor Relations [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa Daily Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
BridgeBio Pharma presented new analyses from its Phase 3 ATTRibute-CM study of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy at the European Society of Cardiology Congress 2026. The findings were simultaneously published in the European Journal of Heart Failure. Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging. Up to half of patients showed clinically meaningful improvement in cardiac function in the completer analysis. Patients treated with acoramidis had 65 additional days alive and out of hospital by Month 36 versus baseline placebo patients. The drug demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups. Acoramidis is an orally administered, near-complete transthyretin stabiliser.
BridgeBio Pharma shares have risen 24% in the past three months, significantly outperforming the S&P 500's 0.7% gain over the same period. The rally extends a 71.4% advance over the past year. Attruby generated $403 million in US sales during the first half of 2026, following $362.4 million in 2025. The drug continued gaining share among treatment-naive patients whilst diagnosed ATTR-CM patients in the United States exceeded 50,000 in 2025. The company faces an FDA decision for BBP-418 by 27 November 2026, with additional regulatory decisions expected for encaleret on 8 May 2027 and infigratinib in early to mid-2027. BBIO trades at 12 times forward enterprise value-to-sales, compared with 2.9 times for its industry peers.
BridgeBio joins CardioHealth Alliance as a new life science partner to advance evidence-based prevention and care. Posted on August 24, 2026 by A M The CardioHealth Alliance welcomes BridgeBio as a new life science partner, further strengthening the Alliance's work to advance evidence-based solutions for the prevention and care of cardiovascular, renal, and metabolic diseases. BridgeBio is a biopharmaceutical company focused on developing transformative medicines for patients with genetic diseases, like transthyretin amyloid cardiomyopathy (ATTR-CM). Through its support of the CardioHealth Alliance, BridgeBio will help advance collaborative efforts to address gaps in cardiovascular care and accelerate the translation of research insights into real-world practice. "BridgeBio was founded to close the gap between genetic discovery and patient care, and cardiovascular disease is where this gap can cost the most lives. Closing this gap requires the kind of cross-disciplinary innovation and collaboration the CardioHealth Alliance was built for. Joining the CardioHealth Alliance will help BridgeBio strengthen the evidence base for turning clinical insight into standard practice." - Jennifer Hodge, PhD, Vice President, Evidence Generation, BridgeBio Established by leaders from the Duke Clinical Research Institute and the Stanford Center for Clinical Research in 2020, the CardioHealth Alliance engages clinicians, data scientists, health care leaders, and policy makers to improve disease care pathways and expedite the implementation of evidence into practice. BridgeBio joins this multidisciplinary group of experts across 13 health systems and five life science partners who are working together to * Use real-world data to inform real-world care * Develop and test new pathways and practices * Scale and optimize best practices * Continuously address value of care through effective policy The Alliance will continue to leverage partnerships with large health systems, academic institutions, and life science partners, including BridgeBio, to manage a broad portfolio of research focused on improving care delivery and outcomes across cardiometabolic conditions. The collaboration aims to address major public health concerns by helping evidence-based therapies and care approaches become integrated into real-world clinical practice. "To accelerate progress in clinical care for people with heart disease, we must embrace a collaborative, cross-disciplinary approach that fosters innovation in how we study health and apply new insights," said Javed Butler, MD, MPH, MBA, Alliance Executive Committee Co-Chair; President, Baylor Scott & White Research Institute; and Senior vice president, Baylor Scott & White Health. "By drawing on the shared expertise of our partners in the CardioHealth Alliance, we can deliver data-informed solutions more quickly to the patients who need them most."